Alnylam Pharmaceuticals Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Alnylam Pharmaceuticals de 60.6% y 20.9% por año respectivamente. Se prevé que el BPA crezca en un 60.1% al año. Se espera que la rentabilidad financiera sea de 68.8% en 3 años.

Información clave

60.6%

Tasa de crecimiento de los beneficios

60.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	21.3%
Tasa de crecimiento de los ingresos	20.8%
Rentabilidad financiera futura	68.8%
Cobertura de analistas	Good
Última actualización	26 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18

Recent updates

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23

Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy

Aug 29

Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity

Aug 18

APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win

Aug 04

Alnylam to target abdominal obesity after research data on gene mutation

Jul 27

Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out

Jul 19

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Jun 21

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ALNY - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3,079	257	673	778	21
12/31/2025	2,269	-243	-28	143	27
12/31/2024	1,853	-515	-233	-102	29
12/31/2023	1,828	-440	42	104	N/A
9/30/2023	1,724	-510	-67	2	N/A
6/30/2023	1,237	-1,064	-541	-473	N/A
3/31/2023	1,143	-1,065	-605	-537	N/A
12/31/2022	1,037	-1,131	-613	-541	N/A
9/30/2022	961	-1,182	-632	-559	N/A
6/30/2022	884	-981	-660	-578	N/A
3/31/2022	880	-893	-654	-577	N/A
12/31/2021	844	-853	-718	-642	N/A
9/30/2021	749	-838	-691	-615	N/A
6/30/2021	688	-887	-653	-591	N/A
3/31/2021	571	-876	-672	-604	N/A
12/31/2020	493	-858	-685	-615	N/A
9/30/2020	401	-891	-775	-688	N/A
6/30/2020	345	-846	-871	-760	N/A
3/31/2020	286	-886	-452	-336	N/A
12/31/2019	220	-886	-419	-278	N/A
9/30/2019	169	-821	-372	-233	N/A
6/30/2019	101	-858	-352	-204	N/A
3/31/2019	86	-802	-745	-595	N/A
12/31/2018	75	-761	-690	-563	N/A
9/30/2018	92	-692	-625	-515	N/A
6/30/2018	107	-570	-550	-460	N/A
3/31/2018	93	-525	-527	-438	N/A
12/31/2017	90	-491	-487	-383	N/A
9/30/2017	69	-462	N/A	-358	N/A
6/30/2017	66	-443	N/A	-335	N/A
3/31/2017	59	-414	N/A	-324	N/A
12/31/2016	47	-410	N/A	-308	N/A
9/30/2016	37	-388	N/A	-282	N/A
6/30/2016	30	-361	N/A	-261	N/A
3/31/2016	30	-342	N/A	-247	N/A
12/31/2015	41	-290	N/A	-189	N/A
9/30/2015	58	-221	N/A	-173	N/A
6/30/2015	62	-188	N/A	-159	N/A
3/31/2015	61	-160	N/A	-150	N/A
12/31/2014	51	-360	N/A	-166	N/A
9/30/2014	37	-371	N/A	-151	N/A
6/30/2014	35	-357	N/A	-132	N/A
3/31/2014	37	-331	N/A	-109	N/A
12/31/2013	47	-89	N/A	-69	N/A
9/30/2013	45	-119	N/A	-115	N/A
6/30/2013	53	-109	N/A	-88	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ALNY sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que ALNY sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ALNY sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (20.9% al año) de ALNY crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (20.9% al año) de ALNY crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ALNY sea muy elevada dentro de 3 años (68.8%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Alnylam Pharmaceuticals Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus estimates of losses per share improve by 10%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Forecast to breakeven in 2026

Consensus revenue estimates increase by 28%

No longer forecast to breakeven

Recent updates

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

Co-Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 10%

CEO & Director recently sold US$1.0m worth of stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam's Huge Opportunity

Forecast to breakeven in 2026

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Chief Innovation Officer notifies of intention to sell stock

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Consensus revenue estimates increase by 28%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

No longer forecast to breakeven

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Consensus EPS estimates fall by 10%

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Insider notifies of intention to sell stock

CEO & Director recently sold US$1.5m worth of stock

Forecast to breakeven in 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$5.98 loss, revenue downgraded

President exercised options and sold US$4.7m worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$1.2m worth of stock

Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Forecast to breakeven in 2025

Alnylam Pharmaceuticals, Inc. Announces Board Changes

Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes

Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

President exercised options to buy US$894k worth of stock.

Board Member notifies of intention to sell stock

Consensus EPS estimates fall by 24%

Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo

Alnylam Pharmaceuticals, Inc. Presents Additional Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy At Heart Failure Society of America Annual Meeting

Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market

Alnylam Pharmaceuticals, Inc. Announces Executive Appointments

Alnylam Pharmaceuticals, Inc. Receives Approval in Europe for AMVUTTRA (Vutrisiran) for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

Alnylam RNAi therapy for rare protein disorder gets EU approval

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals Announces Preliminary Phase 1 Data Supporting the Clinical Advancement of ALN-HSD

Alnylam to offer $900M convertible senior notes

Alnylam Presents Positive Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy

Alnylam Appoints Elliott Sigal, M.D., Ph.D., to Board of Directors